Dipal Doshi - 02 Sep 2025 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: CEO, Director
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol: TRDA
Transactions as of: 02 Sep 2025
Net transactions value: -$47,368
Form type: 4
Filing time: 04 Sep 2025, 17:04:40 UTC
Previous filing: 04 Mar 2025
Next filing: 06 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Doshi Dipal	CEO, Director	C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON	/s/ Jared Cohen, as Attorney-in-Fact	04 Sep 2025	0001613084

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Tax liability	$47,368	-8,723	-2.1%	$5.43	415,664	02 Sep 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.